BioSpace News Archive

Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Gilead Sciences, Inc. announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases.

Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq® plus Avastin® demonstrated a statistically significant improvement in recurrence-free survival in people with hepatocellular carcinoma at high risk of disease recurrence following liver resection or ablation with curative intent.

Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer.

Adela, Inc. presented data demonstrating the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages, when treatment can be most effective.

Volastra Therapeutics released preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research Annual Meeting in Orlando.

DiaCarta, Ltd., a precision molecular diagnostics company, announced that it will present five data posters at the American Association of Cancer Research Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, unveiled new preclinical data on its KRASG12C inhibitor, FMC-376, demonstrating its uniquely differentiated mode of action.

Vivace Therapeutics, Inc. announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research Annual Meeting 2023.

Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.